Sarepta shares plunge on U.K. trial halt, but analyst downplays safety fears

Sarepta Therapeutics confirmed Friday that U.K. regulators have temporarily halted a late-stage trial of two drugs for the muscle-wasting diseases Duchenne muscular dystrophy after one patient experienced a serious medical issue. But one analyst downplayed the incident as an “isolated event.” In a statement, Cambridge-based Sarepta (Nasdaq: SRPT) said the patient’s medical issue “could possibly be related” to the blinded study, in which patients were given one of two drugs, called golodirsen…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news